635678-10-3

Basic information

• Product Name: Methyl 2-aMino-5-Methoxy-4-(1-Methylpiperidin-4-ylMethoxy)benzoate
• Synonyms: Methyl 2-aMino-5-Methoxy-4-(1-Methylpiperidin-4-ylMethoxy)benzoate;Methyl 4-((1-Methylpiperidin-4-yl)Methoxy)-2-aMino-5-Methoxybenzoate
• CAS NO: 635678-10-3
• Molecular Formula: C₁₆H₂₄N₂O₄
• Molecular Weight: 308.37276
• Mol File: 635678-10-3.mol

Chemical Properties

• Boiling Point: 445.6±40.0 °C(Predicted)
• Appearance: /
• Density: 1.137±0.06 g/cm3(Predicted)
• PKA: 9.05±0.10(Predicted)
• CAS DataBase Reference: Methyl 2-aMino-5-Methoxy-4-(1-Methylpiperidin-4-ylMethoxy)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-aMino-5-Methoxy-4-(1-Methylpiperidin-4-ylMethoxy)benzoate(635678-10-3)
• EPA Substance Registry System: Methyl 2-aMino-5-Methoxy-4-(1-Methylpiperidin-4-ylMethoxy)benzoate(635678-10-3)

Safety Data

• Hazardous Substances Data: 635678-10-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-aMino-5-Methoxy-4-(1-Methylpiperidin-4-ylMethoxy)benzoate is used as an intermediate in the synthesis of local anesthetics and antiarrhythmic medications for the treatment of various medical conditions.
Used in Medical Research:
Methyl 2-aMino-5-Methoxy-4-(1-Methylpiperidin-4-ylMethoxy)benzoate is used as a research tool to study the properties and mechanisms of action of local anesthetics and antiarrhythmic medications, contributing to the development of new and improved therapies.
Used in Drug Development:
Methyl 2-aMino-5-Methoxy-4-(1-Methylpiperidin-4-ylMethoxy)benzoate is utilized in the development of new drugs with potential applications in treating pain and cardiac arrhythmias, enhancing the safety and efficacy of existing treatments.

Upstream product

• 166815-96-9 N-tert-butoxycarbonyl-4-(4-toluenesulphonyloxymethyl)piperidine 
• 906565-52-4 methyl 3-methoxy-4-(1-tert-butyloxycarbonylpiperidin-4-ylmethoxy)benzoate 
• 635678-09-0 methyl 3-methoxy-4-(1-methylpiperidin-4-ylmethoxy)benzoate 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 906565-53-5 methyl 5-methoxy-4-(1-methylpiperidin-4-ylmethoxy)-2-nitrobenzoate 

Downstream Products

• 264208-69-7 6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-3,4-dihydroxyquinazolin-4-one 
• 264208-72-2 4-chloro-6-methoxy-7-[(1'-methylpiperidin-4'-yl)methoxy]-quinazoline 

Relevant articles and documents

QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF

Related to a quinazoline compound serving as an EFGR triple mutation inhibitor and applications thereof. Specifically, disclosed are a compound as represented by the following formula (I), a pharmaceutical composition comprising the compound of formula (I

Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S

In this paper, we describe the discovery and optimization of a series of noncovalent reversible epidermal growth factor receptor inhibitors of EGFRL858R/T790M/C797S. One of the most promising compounds, 25g, inhibited the enzymatic activity of EGFRL858R/T790M/C797S with an IC50 value of 2.2 nM. Cell proliferation assays showed that 25g effectively and selectively inhibited the growth of EGFRL858R/T790M/C797S-dependent cells. This series of compounds, which occupy both the ATP binding site and the allosteric site of the EGFR kinase, may serve as a basis for the development of fourth-generation EGFR inhibitors for L858R/T790M/C797S mutants.

Fluorine-18 labeling of 6,7-disubstituted anilinoquinazoline derivatives for positron emission tomography (PET) imaging of tyrosine kinase receptors: Synthesis of18F-Iressa and related molecular probes

Inhibitors of tyrosine kinase enzymatic activity represent a promising new class of antineoplastic agents. Although clinical studies performed over the last decade give more insight on the potential therapeutic applications of such drugs, identification of the individual patients who might benefit from them remains a major challenge. We have developed a synthetic strategy for the production of a wide variety of radiolabeled 6,7-disubstituted 4-anilinoquinazolines suitable for noninvasive imaging of tyrosine kinase receptors to predict therapy effectiveness. Three new F-18 labeled radiopharmaceuticals based on the therapeutic agents Tarceva, Iressa, and ZD6474 were synthesized. Decay-corrected yields varied between 25 and 40% for a total synthesis time of 120 min, thus providing F-18 labeled tyrosine kinase inhibitors in quantities and times practical for use as PET radiopharmaceuticals. Copyright

Investigation of the effect of varying the 4-anilino and 7-alkoxy groups of 3-quinolinecarbonitriles on the inhibition of Src kinase activity

Several 7-alkoxy-4-anilino-3-quinolinecarbonitriles were synthesized and evaluated for Src kinase inhibitory activity. Optimal inhibition of both Src enzymatic and cellular activity was seen with analogues having a 2,4-dichloro-5-methoxyaniline group at C-4. Compound 18, which has a 1-methylpiperidinemethoxy group at C-7, showed in vivo activity in a xenograft model.